Craving, Binge Eating and Obesity

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Binge Eating Disorder, Obesity

In brief

This research study is designed to look at the effectiveness of bupropion for reducing binge eating in overweight persons with binge eating problems. Participants in the study will receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for eight weeks. In addition, participants will be given the option to receive 8 weeks of free behavioral weight loss treatment. This treatment, known to be effective for reducing binge eating and helping people lose weight, will be administered following the medication phase and at no cost. It is expected that compared to placebo, bupropion will produce greater reductions in binge eating.

Key facts

Study ID

NCT00414167

Run by

Yale University

People needed

61

Starts

2005-12-01

Expected to finish

2011-03-01

Last updated by the study team

2020-04-03

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• BMI 25-50
• Able to travel to clinical site (New Haven, CT) for bi-weekly visits.

You may not qualify if…

• Predisposition to seizures
• History of anorexia or bulimia nervosa
• Current Type I or Type II diabetes mellitus

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.